Statistics

Total Visits

Views
Pazopanib (Pz) as first line for metastatic renal carcinoma (mRC): Updated validation of the international metastatic renal-cell carcinoma database consortium prognostic model (IMRCC). The SPAZO study (SOGUG)23

Select a period of time:

Number of views in the range

Views
Pazopanib (Pz) as first line for metastatic renal carcinoma (mRC): Updated validation of the international metastatic renal-cell carcinoma database consortium prognostic model (IMRCC). The SPAZO study (SOGUG)15

Views

Views
October 20240
November 20240
December 20240
January 20250
February 20250
March 202515
April 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore15
 

Top cities views

Views